Zai Lab Limited Stock

Equities

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
17.78 USD -2.25% Intraday chart for Zai Lab Limited -0.78% -34.94%
Sales 2024 * 389M Sales 2025 * 617M Capitalization 1.76B
Net income 2024 * -277M Net income 2025 * -130M EV / Sales 2024 * 3.15 x
Net cash position 2024 * 538M Net cash position 2025 * 275M EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
-6.47 x
P/E ratio 2025 *
-16.6 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
1.12%
Free-Float 9.91%
More Fundamentals * Assessed data
Dynamic Chart
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis CI
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment MT
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro MT
Zai Lab's Cancer Drug Gets NDA Approval in China MT
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA CI
Zai Lab's Shares Rise After Q1 Beat MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
More news
1 day-2.25%
1 week-0.78%
1 month+12.53%
3 months-15.25%
6 months-34.85%
Current year-34.94%
More quotes
1 week
17.52
Extreme 17.52
19.19
1 month
15.80
Extreme 15.8016
22.35
Current year
13.48
Extreme 13.48
27.87
1 year
13.48
Extreme 13.48
37.92
3 years
13.48
Extreme 13.48
181.92
5 years
13.48
Extreme 13.48
193.54
10 years
13.48
Extreme 13.48
193.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 14-03-31
Director of Finance/CFO 56 21-08-31
President 54 22-07-31
Members of the board TitleAgeSince
Director/Board Member 81 16-12-31
Director/Board Member 73 16-12-31
Director/Board Member 66 18-12-31
More insiders
Date Price Change Volume
24-05-31 17.78 -2.25% 1,628,385
24-05-30 18.19 +1.28% 965,527
24-05-29 17.96 -2.71% 356,007
24-05-28 18.46 +3.01% 267,131
24-05-24 17.92 -5.98% 878,622

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.78 USD
Average target price
51.37 USD
Spread / Average Target
+188.93%
Consensus